Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes. The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects With Acute Coronary Syndrome)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes. The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects With Acute Coronary Syndrome)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Thienopyridines
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATLAS-ACS-TIMI-46
  • Sponsors Bayer
  • Most Recent Events

    • 14 Nov 2018 Results assessing the association between D-Dimer Levels and Clinical Outcomes in Acute Coronary Syndrome Patients (n=1,834) presented at the 91st Annual Scientific Sessions of the American Heart Association
    • 31 Aug 2018 Biomarkers information updated
    • 04 Aug 2018 Results of a substudy in a subset of subjects (n =1834) assessing the D-dimer levels and the effect of Rivaroxaban on those levels and outcomes in patients with acute coronary syndrome, published in the American Journal of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top